Hihara A
Clarivate, Paris, France.
Drugs Today (Barc). 2020 Dec;56(12):787-793. doi: 10.1358/dot.2020.56.12.3255085.
As many other conferences held in 2020, the 17th Drug Information Association (DIA) Japan Annual Meeting 2020 was held virtually for the first time due to the COVID-19 crisis. The virtual platform delivered 64 sessions across 3 days and allowed participants to join the sessions flexibly, interactively participate in Q and A and connect with fellows without boundaries. The opening speech was addressed by Hajime Saijo (DIA Japan) to introduce the conference theme "Beyond Innovation" and key sessions featured discussions on future healthcare, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 30-year anniversary, the Pharmaceuticals and Medical Devices Agency (PMDA) town hall, patient-focused drug development and global drug development. This meeting report covers the topics discussed from the programs featuring patient engagement, innovative drug development and new technologies.
与2020年举办的许多其他会议一样,由于新冠疫情危机,第17届日本药物信息协会(DIA)2020年年会首次以线上形式举行。虚拟平台在3天内提供了64场会议,让参与者能够灵活地加入会议,以互动方式参与问答,并与同行进行无界限交流。开幕式由日本药物信息协会的斋藤肇发表讲话,介绍会议主题“超越创新”,主要会议环节围绕未来医疗保健、人用药品注册技术国际协调理事会(ICH)成立30周年、日本药品和医疗器械管理局(PMDA)市政厅会议、以患者为中心的药物研发以及全球药物研发展开讨论。本会议报告涵盖了从以患者参与、创新药物研发和新技术为特色的议程中讨论的主题。